Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avalo Therapeutics Inc AVTX

Healthcare Biotechnology
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1ß mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1ß (IL-1ß... see more

Recent & Breaking News (NDAQ:AVTX)

Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference

GlobeNewswire March 7, 2023

Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants

GlobeNewswire February 2, 2023

Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire February 2, 2023

Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

GlobeNewswire January 17, 2023

Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates

GlobeNewswire November 7, 2022

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

GlobeNewswire November 7, 2022

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

GlobeNewswire September 6, 2022

Avalo to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire September 1, 2022

Avalo Therapeutics Announces Board Changes

GlobeNewswire August 11, 2022

Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

GlobeNewswire August 4, 2022

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

GlobeNewswire August 2, 2022

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics

GlobeNewswire August 1, 2022

Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split

GlobeNewswire July 6, 2022

Avalo to Present at the 2022 Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)

GlobeNewswire May 18, 2022

Avalo to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire May 17, 2022

Avalo Therapeutics First Quarter 2022 Financial Results and Business Updates

GlobeNewswire May 5, 2022

Avalo to Present at Oppenheimer's 32nd Annual Healthcare Conference

GlobeNewswire March 8, 2022

Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates

GlobeNewswire March 2, 2022

Avalo Therapeutics Announces Leadership Transition

GlobeNewswire February 17, 2022